Project Grant R01DA060755

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $1.4M
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $2,223,769 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of California, San Diego (UCSD) to investigate the individual and combined impact of HIV and opioids on inflammasome-mediated neuroinflammation and neurotoxicity. The 5-year study, which commenced on April 15, 2025, aims to uncover the mechanistic intersection between HIV and opioids that leads to more severe neurological...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $234,000 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids like fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, and to use a novel dual fluorescent and bioluminescent virus to...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 to the Regents of the University of California at Riverside to investigate the role of methamphetamine and cysteinyl leukotrienes in HIV persistence. The research aims to: 1) Determine how methamphetamine engages the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis to increase HIV infection of CD4+ T-cells and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to spatially characterize HIV-host cellular interactions in the central nervous system (CNS) of people with HIV (PWH) who died suddenly. The $983,672 award will fund the development and implementation of innovative single-cell and spatial genomic assays to analyze the localization, distribution, and activity of HIV-infected...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded a $1,372,480 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division. The 5-year grant, effective April 15, 2025 through January 31, 2030, will fund research to elucidate the molecular mechanisms by which the interplay of HIV transactivator of transcription...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research focused on understanding the role of HIV proteins in psychostimulant abuse. The $1,465,275 grant, awarded on May 1, 2025, will enable researchers at the University of Alabama at Birmingham (UAB) to investigate how the HIV Trans-Activator of Transcription (Tat) protein modulates the effects of amphetamine on dopamine...
This $1,454,724 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to understand the mechanisms involved in HIV-1 latency in the central nervous system (CNS). The primary objectives are to identify key factors, pathways, and regulators that determine the establishment, maintenance, and reactivation of latent HIV-1 virus in brain myeloid cell lineages, such as microglia and macrophages. The research will...
The National Institutes of Health (NIH) Office of the Director awarded a 5-year, $498,444 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Administrators of Tulane Educational Fund, doing business as Tulane University. The grant supports research to investigate the effects of HIV-associated extracellular vesicles on mitochondrial dysfunction and blood-brain barrier disruption in brain microvessels. The goal is to explore how HIV-free extracellular vesicles...
The National Institutes of Health (NIH), through the Mental Health Research Grants program (CFDA 93.242) administered by the National Institute of Mental Health (NIMH), has awarded a $434,500 R21 grant to the University of California, San Diego (UCSD) to investigate the epigenetic mechanisms controlling HIV latency and neuropathogenesis in microglia. The project aims to use single-cell multi-omics approaches and state-of-the-art sequencing technologies to characterize the transcriptomic and...
This Project Grant award, totaling $1,481,760 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate how methamphetamine (MA) use promotes immune dysfunction in people living with HIV (PWH) even during antiretroviral therapy (ART) suppression. The research aims to determine how MA-induced activation of the NLRP3 inflammasome leads to altered metabolism, epigenetics, and immune dysfunction in T...

HIV TAT AND OPIATE-MEDIATED ABERRATIONS IN GLIAL-NEURONAL CROSSTALK: IMPLICATIONS FOR THE ROLE OF EXTRACELLULAR RNA IN HAND - PROJECT SUMMARY: CURRENTLY, THERE ARE OVER 40 MILLION PEOPLE LIVING WITH HIV-1 WORLDWIDE. ALTHOUGH COMBINATION ANTIRETROVIRAL THERAPY (CART) HAS IMPROVED THE HEALTH AND LIFESPAN OF MILLIONS OF THOSE LIVING WITH HIV-1, LONG-TERM USE OF ANTIRETROVIRALS COUPLED WITH LIMITED PENETRATION OF SOME OF THESE MEDICATIONS INTO THE CNS, IS OFTEN ACCOMPANIED WITH NEUROCOGNITIVE IMPAIRMENTS IN AT LEAST 50% OF INFECTED INDIVIDUALS, COMMONLY REFERRED TO AS NEUROHIV. ADDITIONALLY, WHILE CART CAN SUCCESSFULLY SUPPRESS PERIPHERAL VIREMIA, PERSISTENCE OF CYTOTOXICITY VIRAL PROTEIN SUCH AS TRANSACTIVATOR OF TRANSCRIPTION (TAT) IN TISSUES SUCH AS THE BRAIN, REMAINS A SIGNIFICANT CONCERN. ADDING FURTHER COMPLEXITY IS THE CO-MORBIDITY OF DRUG USE DISORDER IN THOSE INFECTED WITH HIV-1, ESPECIALLY THAT OF OPIATES. WHILE THE DIRECT COMBINED EFFECTS OF HIV TAT AND OPIATES INVOLVING ASTROCYTIC CYTOKINES AND CHEMOKINES ON NEURONAL INJURY ARE WELL STUDIED, HOW MORPHINE EXACERBATES ABERRANT GLIAL-NEURONAL RESPONSES TO TAT & HIV-1, INVOLVING SHUTTLING OF MICRORNAS AND REPROGRAMMING THE NEURONS TO A SYNAPTICALLY INJURED PHENOTYPE IN IS AN UNMET NEED IN THE FIELD AND WARRANTS INVESTIGATION. OUR PRELIMINARY FINDINGS SUGGEST IN HUMAN PRIMARY ASTROCYTES/ A172 CELLS EXPOSURE TO HIV TAT MEDIATED THE INDUCTION AND RELEASE OF MIRNA-7 AND EXPOSURE TO MORPHINE MEDIATED THE UPREGULATION AND RELEASE OF MIR-23A IN EXTRACELLULAR VESICLES (EVS). FURTHERMORE, NEURONAL UPTAKE OF TAT AND MORPHINE STIMULATED ASTROCYTE EVS (CONTAINING MIR-7 AND 23A) RESULTED IN EXACERBATED SYNAPTIC INJURY COMPARED TO UPTAKE BY EVS WITH INDIVIDUAL MIR. THESE FINDINGS ARE BACKED BY STRONG IN VIVO DATA DEMONSTRATING MORPHINE-MEDIATED POTENTIATION OF SYNAPTODEGENERATION INDUCED BY HIV TAT AND ALSO, REVERSAL OF SYNATIC INJURY BY ANTI-MIR. TAKEN TOGETHER, THE SCIENTIFIC HYPOTHESIS OF THIS PROPOSAL IS THAT HIV TAT/HIV-1 & MORPHINE CO- OPERATE TO MEDIATE EXACERBATED SYNAPTIC ALTERATIONS INVOLVING: A) HIV TAT/ HIV-1-MEDIATED RELEASE OF ASTROCYTIC EV MIR-7 THAT DOWNREGULATES ITS TARGETS (NLGN2, GRIN2A, PBX3), & B) MORPHINE-MEDIATED RELEASE OF ASTROCYTIC EV MIR-23A DOWNREGULATES ITS TARGETS (NRGN, PCLO, NLGN1), IN NEURONS. WE WILL TEST THE EFFICACY OF ENGINEERED, ASTROCYTE SPECIFIC AAVS EXPRESSING SHORT HAIRPIN RNA FOR -MIR7 & -23A TO RESTORE HIV-1 TAT & MORPHINE-MEDIATED SYNAPTIC IMPAIRMENTS IN TWO COMPLEMENTARY IN VIVO RODENT MODELS OF NEUROHIV: A) INDUCIBLE BRAIN TAT TRANSGENIC & B) INFECTIOUS HUMANIZED MICE ADMINISTERED OPIATES ALONG WITH VALIDATION IN ARCHIVAL MACAQUE BRAIN TISSUES. THESE STUDIES WILL MAKE A SIGNIFICANT CONTRIBUTION TO OUR UNDERSTANDING OF GLIAL-NEURONAL CROSSTALK, AND THE ROLE OF MIRNAS IN HIV AND OPIATE-MEDIATED SYNAPTIC NEURODEGENERATION AND WILL SET A STAGE FOR A FUTURE DEVELOPMENT OF RNA THERAPEUTICS FOR THESE COMORBID CONDITIONS.

Posted 6/14/24, 12:00 AM